Market Overview
The global varicella attenuated live vaccine market size was valued at USD 2441 million in 2024. The market is projected to grow from USD 2560 million in 2025 to USD 3331 million by 2032, exhibiting a CAGR of 4.7% during the forecast period.
Varicella attenuated live vaccines are biological preparations derived from the Oka strain of varicellazoster virus (VZV), specifically engineered to provide immunity against chickenpox. These vaccines contain weakened live viruses that stimulate an immune response without causing the disease, offering long-term protection. The two primary types available are monovalent vaccines (targeting only varicella) and combination vaccines (such as MMRV, which protects against measles, mumps, rubella, and varicella).
3331 million by 2032 USD 2441 million in 2024
Monovalent Vaccine Segment Dominates Owing to Established Efficacy and Regulatory
Approvals
The market is segmented based on type into:
Monovalent Vaccine
Subtypes: Standalone varicella prevention vaccines
Combination Vaccine
Subtypes: MMRV (measles, mumps, rubella, varicella) and other combinations
By Application
Kids Injection Segment Leads Due to Universal Vaccination Programs in Multiple Countries
The market is segmented based on application into: Kids Injection Adults Injection
Portable Neuromonitoring Device Market
Our Key Players
Merck & Co., Inc. (U.S.)
BCHT (China National Biotec Group) (China)
Shanghai Institute of Biological Products (China)
GSK plc (U.K.)
Keygen Biological Products (China)
Green Cross Corp (South Korea)
